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Background: We investigated the effects of anthropometric, laboratory, and lifestyle
factors on the development of non-alcoholic fatty liver disease (NAFLD) in a nationwide,
population-based, 4-year retrospective cohort.
Methods: The propensity score-matched study and control groups contained 1,474
subjects who had data in the Korean National Health Insurance Service-National Sample
Cohort in 2009, 2011, and 2013. NAFLD was defined using medical records of a
diagnosis confirmed by primary clinicians and meeting two previously validated fatty
liver prediction models. Chronological changes in anthropometric variables, laboratory
results, and lifestyle factors during two periods were compared between patient and
control groups in order to find out parameters with consistent dynamics in pre-NAFLD
stage which was defined as period just before the NAFLD development.
Results: Among the 5 anthropometric, 10 laboratory, and 3 lifestyle factors, prominent
chronological decremental changes in serum triglycerides were consistently observed
during the pre-NAFLD stage, although the degrees of changes were more predominant
in men (−9.46 mg/dL) than women (−5.98 mg/dL). Furthermore, weight and waist
circumference changes during the pre-NAFLD stage were noticeable only in women
(+0.36 kg and+0.9 cm for weight and waist circumference, respectively), which suggest
gender difference in NAFLD.
Conclusion: Early screening strategies for people with abrupt chronological
changes in serum triglycerides to predict NAFLD development before the progression
is recommended.
Keywords: non-alcoholic fatty liver disease, laboratory results, lifestyle factors, serum triglyceride, nationwide
study
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD), a disease complex
spectrum ranging from benign hepatic steatosis to hepatic
inflammation, fibrosis, and cirrhosis, is now the leading cause of
chronic liver disease in developed countries (1). In Korea, the
prevalence of fatty liver is estimated to be as high as 25–30%
(2), and 10–15% of those affected could have steatohepatitis with
inflammation. Because metabolic syndrome components such as
obesity and diabetes are independent predictors of NAFLD (3),
many reports emphasize comprehensive lifestyle modifications
based on reduced energy intake and increased physical activity as
a primary therapeutic intervention for NAFLD (4–7). Although
systematic guidelines for NAFLD assessment and management
proposed by the National Institute for Health and Care
Excellence (NICE) recommend ultrasonography as the first-line
diagnostic step and lifestyle intervention for management of
NAFLD (8), few publication has previously reported data on
changes in NAFLD-associated parameters from a chronological
viewpoint (9), and none using real-world human clinical data.
As the early detection of NAFLD becomes more important,
identification of early changes that predict future NAFLD
development and chronological changes in parameters evaluated
in the national health screening examination is essential to
both the clinical field and national policy. Korea has systematic
and comprehensive national registry data collected from the
Korean National Health Insurance Service-National Sample
Cohort (KNHIS-NSC) (10). The KNHIS-NSC database is a
population-based sample cohort. Its purpose is to provide
representative, useful health insurance and health examination
data to public health researchers and policymakers. A total of
1,025,340 participants (513,258 men and 512,082 women), 2.2%
of the total eligible population in the 2002 Korean nationwide
health insurance database, were selected using proportionally
allocated, stratified, systematic random sampling with a total
medical expenses distribution within strata reflecting gender, age
group, qualifications, and income quintile. Importantly, the data
include laboratory results from general health examinations of
cohort participants that were followed for 11-years, until 2013.
The purpose of this study was to investigate the effects of
anthropometric, laboratory, and lifestyle factors recorded in
the KNHIS-NSC database on the development of NAFLD in a
nationwide, population-based, 4-year retrospective cohort.
MATERIALS AND METHODS
Database
In Korea, all citizens are obligated to enroll in the KNHIS.
A total of 97% of the Korean population is covered by the
Medical Assistance Program, and 3% of the Korean population
is covered by the Medical Care for Patriots and Veterans Affairs
Scheme, respectively. Thus, nearly all of the data in the health
system are centralized in large databases. In Korea, patients with
KNHIS pay ∼30% of their total medical expenses, and medical
providers are required to submit claims for the remaining 70%.
Claims are accompanied by data regarding diagnostic codes,
procedures, prescription drugs, personal information about the
patient, information about the hospital, the direct medical costs
of both inpatient and outpatient care, and dental services. No
health care records are duplicated or omitted because all Korean
residents receive a unique identification number at birth for
use by the Korean government for purposes related to the
health care system. For diagnostic codes, the KNHIS uses the
Korean Classification of Diseases (KCD), which is similar to the
International Classification of Diseases (ICD).
This study adhered to the tenets of the Declaration of Helsinki,
and the KNHIS-NSC 2002–2013 project was approved by the
Institutional Review Board of the KNHIS. This study design was
reviewed and approved by the Institutional Review Board of
the National Health Insurance Service, Ilsan Hospital (IRB No.
2015-11-010). Written informed consent was waived.
Study Population
Data for this study were derived from the KNHIS-NSC 2009–
2013. This database includes all medical claims and general health
examination results filed from January 2009 to December 2013.
The study population for this study was nationally representative
subjects who have undertaken annual medical check-ups in all
three of the following years: 2009, 2011, and 2013.
A flowchart for the study population is in Figure 1A.
From a total of 108,653 Koreans who participated in medical
check-ups in all 3-years (2009, 2011, and 2013), we excluded
subjects with a history of liver disease before 2009 (n =
37,934) using the KNHIS-NSC 2002–2008 database. Then, we
selected individuals who were newly diagnosed with NAFLD in
2011 or 2013 (The criteria for NAFLD diagnosis is explained
in section Definition of NAFLD). Among the 1,775 subjects
newly diagnosed with NAFLD in 2011 or 2013, we excluded
those missing anthropometric, biochemical, medical history, or
lifestyle variables that we examined in this study (n = 968).
Thus, we analyzed a total of 737 NAFLD patients (470 men
and 267 women) for this study. We derived a control group
(470 men and 267 women) from the whole population without
an NAFLD diagnosis (n = 46,671) using a propensity score
matching algorithm for age and gender. All subjects in the control
group received negative results when evaluated by the hepatic
steatosis index and fatty liver index using laboratory results from
2009, 2011, and 2013.
We further divided the NAFLD group into subgroups
(Figure 1B). Group 1 was defined as subjects who did not have
a diagnosis of NAFLD in 2009 or 2011 but who had newly
developed NAFLD in 2013. Group 2 was defined as subjects who
did not have a diagnosis of NAFLD in 2009 but showed newly
developedNAFLD in 2011 and sustained the diagnosis of NAFLD
in 2013.
Study Period
Because time-dependent changes in various factors were the
major end-point result, we assigned chronological differences
from 2009 to 2011 as the first period and chronological
differences from 2011 to 2013 as the second period (Figure 1B).
“Pre-NAFLD stage” was defined as the period just before
the NAFLD development for patient groups. Therefore, the
first period was the pre-NAFLD stage for group 2, and
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FIGURE 1 | Overview of the study design. (A) Flowchart of study population selection. (B) Designations for subgroups of the non-alcoholic fatty liver disease group
and for the control group. Changes were evaluated during two periods.
the second period was the pre-NAFLD stage for group 1.
Although the data did not contain the exact time when
NAFLD developed in each patient, we assumed a 2-year
difference for both the first and the second periods as an
approximate value.
Definition of NAFLD
Each patient was tracked on the basis of his or her index dates for
ambulatory and inpatient care visits over the 11-years from 2003
to 2013, to detect those patients who developed NAFLD (KCD
code K76.0, corresponding to ICD-10-CM code K76.0). To rule
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out the effects of liver disease with other etiologies, we excluded
subjects who also had a diagnosis of alcoholic fatty liver or toxic
liver (KCD codes K70–75).
To confirm the medical diagnosis of NAFLD as assessed
by patients’ primary physicians, we calculated two previously
validated fatty liver predictionmodels: (1) hepatic steatosis inde×
(HSI) = 8 × [alanine transferase (ALT)/aspartate transferase
(AST) ratio] + body mass index (BMI) (+2, if female; +2, if
diabetes mellitus) (11) and (2) fatty liver index (FLI) = [[e∧
[0.953 × loge [triglycerides (TG)] + 0.139 × BMI + 0.718
× loge [gamma-glutamyl transferase (GGT)] + 0.053 × waist
circumference −15.745]]]/[[1+e∧ [0.953 × loge (TG) + 0.139
× BMI + 0.718 × loge (GGT) + 0.053 × waist circumference
−15.745]]]× 100, with TGmeasured inmg/dL, GGT in U/L, and
waist circumference in cm (12). All parameters for the equations
were available in the database. We defined NAFLD as HSI of 35
or higher or FLI of 60 or higher, following a previous study (13).
Anthropometric, Laboratory, and Lifestyle
Variables
We chronologically compared 18 variables in all subjects in the
3 groups, calculating absolute differences of mean values for
numerical parameters and percentage differences for categorical
parameters from 2009 to 2011 and from 2011 to 2013. As the time
intervals were both ∼2-years, we could also compare changes
between 2 time periods within each group.
For anthropometric factors, we evaluated body weight, BMI,
systolic blood pressure (SBP), diastolic blood pressure (DBP), and
waist circumference. Body weight was measured to the nearest
0.1 kg. BMI was calculated as weight/height2 (kg/m2). Waist
circumference was measured at the narrowest point between the
lower border of the rib cage and the iliac crest.
For laboratory values, we measured a total of 10 parameters
in blood samples: liver enzymes (AST, ALT, and GGT), fasting
glucose, total cholesterol, TG, high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol, creatinine
in serum samples, and hemoglobin level in whole blood sample.
For the lifestyle evaluation, we reviewed questionnaires related
to smoking, alcohol drinking, and exercise status. Because all
questions were answered based on each individual’s experience,
we objectively categorized answers into binary outcomes for
smoking (current smoking or not) and exercise (no exercise at all
or at least minimal physical activity). For alcohol consumption,
we scored an alcohol index according to the following criteria: 0
= no consumption, 1= alcohol fewer than or equal to 2 days per
week, 2 = alcohol more than 3 days and fewer than or equal to 4
days per week, 3= alcohol more than 5 days per week.
For the family history investigation, baseline profiling
on hypertension, stroke, cardiovascular disease, and diabetes
mellitus were incorporated for only available participants based
on self-check questionnaires.
Statistical Methods
Participants’ characteristics were compared using independent-
sample Student’s t-tests for continuous variables and Chi-square
tests for categorical variables. The differences between the 2
NAFLD subgroups and control group were verified by ANOVA
test. All data are presented as mean ± standard deviation for
continuous variables and frequency percentages for categorical
variables. P < 0.05 were considered statistically significant.
All analyses were conducted using SAS v9.4 (SAS Institute
Inc., USA).
RESULTS
Characteristics of the Study Population
The clinical features of the study population at baseline (2009)
are shown in Table 1. Because propensity score matching was
based on age group and gender, the NAFLD group and control
group were the same in terms of age group distribution and
gender percentages. All tested anthropometric factors were
statistically significantly higher in the NAFLD group than in the
control group, with the exception of height. Considering the
laboratory variablemeasurements, all three liver enzymes showed
statistically significant differences between theNAFLD group and
the control group in both genders, as expected. Interestingly,
serum HDL cholesterol level was lower in the NAFLD group
than in the control group with statistical significance in men
but without statistical significance in women. Additionally,
the NAFLD group showed higher LDL cholesterol than the
control group with statistical significance in women but without
statistical significance in men. For the lifestyle parameters, we
found no statistically significant differences in either gender for
any variable (smoking, alcohol consumption, or exercise status).
For the family history variables, men in the NAFLD group
appeared to report more family history of hypertension and
diabetes mellitus compared to the control group, which was not
observed in women.
Chronological Changes in Anthropometric
and Laboratory Parameters in the NAFLD
Subgroups
We compared the time-dependent changes in anthropometric
and laboratory parameters by absolute mean value differences
among the 2 NAFLD subgroups and the control group by gender
(Figure 2). When liver enzyme dynamics during pre-NAFLD
stage were evaluated, AST, ALT, and GGT all increased in group 2
during the first period (2009–2011) with statistical significance in
men, but not in women. Furthermore, during the second period
(2011–2013), AST, ALT, and GGT all increased in group 1 and
decreased in group 2 with statistical significance in both genders,
as expected (Figure 2, green box).
Importantly, serum TG in both group 1 and group 2 showed
the most prominent decrease during pre-NAFLD stages in
both genders (Figure 2, red box). Interestingly, the decremental
change of serum TG inmen for group 2 during pre-NAFLD stage
was most prominent with statistical significance (p < 0.05). The
average degree of decrease in serum TG level among NAFLD
patient groups compared to control group in pre-NAFLD stages
was 8.38mg/dL. Additionally, total cholesterol in females showed
the most significant decrease in group 2 during the first period
and in group 1 during the second period, although statistical
significance was observed only in the first period.
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TABLE 1 | Clinical characteristics of study population measured in year 2009 as baseline characteristics.
Gender Male Female
NAFLD Normal p-value NAFLD Normal p-value
(N = 470) (N = 470) (N = 267) (N = 267)
DEMOGRAPHIC FACTORS [NUMBER, (%)]
Age group (years)
20–29 35 (7.4) 35 (7.4) 1.00 1 (0.4) 1 (0.4) 1.00
30–39 128 (27.2) 128 (27.2) 10 (3.7) 10 (3.7)
40–49 152 (32.3) 152 (32.3) 56 (21.0) 56 (21.0)
50–59 91 (19.4) 91 (19.4) 115 (43.1) 115 (43.1)
60–69 51 (10.9) 51 (10.9) 64 (24.0) 64 (24.0)
>70 13 (2.8) 13 (2.8) 21 (7.9) 21 (7.9)
ANTHROPOMETRIC FACTORS [MEAN, (SD)]
Height (cm) 170.5 (6.4) 170.0 (5.8) 0.2408 155.0 (5.6) 155.3 (5.9) 0.5550
Weight (kg) 78.6 (9.7) 66.2 (7.7) <.0001 64.5 (7.7) 54.1 (5.4) <.0001
Waist circumference (cm) 90.1 (7.2) 80.5 (6.1) <.0001 84.9 (7.9) 75.0 (6.4) <.0001
Body mass index (kg/m2 ) 27.0 (2.8) 22.9 (2.1) <.0001 26.8 (2.7) 22.5 (2.0) <.0001
Systolic blood pressure (mmHg) 127.1 (13.3) 123.6 (13.0) <.0001 126.8 (14.5) 122.5 (16.0) 0.0012
Diastolic blood pressure (mmHg) 80.2 (9.3) 77.2 (9.0) <.0001 77.9 (9.2) 75.2 (9.5) 0.0008
LABORATORY RESULTS [MEAN, (SD)]
Hemoglobin (g/dl) 15.3 (1.2) 14.9 (1.1) <.0001 13.0 (1.3) 12.8 (1.0) 0.0302
Fasting glucose (mg/dL) 103.7 (26.7) 95.7 (20.2) <.0001 101.1 (25.2) 93.6 (15.9) <.0001
Total cholesterol (mg/dL) 202.3 (36.8) 192.1 (34.0) <.0001 208.0 (41.9) 199.4 (36.9) 0.0127
Triglycerides (mg/dL) 196.4 (125.6) 134.7 (101.9) <.0001 143.7 (81.2) 108.4 (67.8) <.0001
HDL cholesterol (mg/dL) 49.0 (11.1) 55.1 (22.5) <.0001 58.5 (61.9) 60.6 (43.7) 0.6575
LDL cholesterol (mg/dL) 115.1 (46.6) 111.1 (31.4) 0.1302 125.5 (37.2) 119.3 (33.9) 0.0456
Serum creatinine (mg/dL) 1.4 (2.0) 1.4 (2.0) 0.8944 0.9 (0.8) 0.9 (0.7) 0.8474
AST (U/L) 33.1 (16.3) 24.8 (19.6) <.0001 30.2 (30.6) 23.4 (13.1) 0.001
ALT (U/L) 50.8 (32.7) 21.8 (9.7) <.0001 37.3 (44.7) 17.4 (8.7) <.0001
GGT (U/L) 71.0 (67.4) 36.0 (29.2) <.0001 36.2 (53.8) 18.3 (10.2) <.0001
FAMILY HISTORY* [NUMBER, (%)]
Hypertension 74 (22.6) 27 (8.3) <.0001 36 (21.6) 34 (20.7) 0.8542
Stroke 44 (13.5) 30 (9.3) 0.0917 24 (14.4) 24 (14.8) 0.9093
Cardiovascular disease 16 (4.9) 7 (2.2) 0.059 14 (8.4) 7 (4.3) 0.1318
Diabetes mellitus 59 (18.0) 31 (9.6) 0.0018 30 (18.0) 22 (13.5) 0.2655
LIFE STYLE FACTORS [NUMBER, (%)]
Smoke 0.5538 0.0798
No 261 (55.5) 270 (57.4) 264 (98.9) 258 (96.6)
Current smoker 209 (44.5) 200 (42.6) 3 (1.1) 9 (3.4)
Alcohol consumption (days/a week) 0.1812 0.4846
0: 0 152 (32.3) 137 (29.1) 218 (81.6) 222 (83.1)
1–2: 1 220 (46.8) 244 (51.9) 44 (16.5) 39 (14.6)
3–4: 2 77 (16.4) 61 (13.0) 5 (1.9) 4 (1.5)
>5: 3 21 (4.5) 28 (6.0) 0 (0.0) 2 (0.7)
Exercise 0.1691 0.2552
No 90 (19.1) 74 (15.7) 73 (27.3) 85 (31.8)
Yes (at least little physical activity) 380 (80.9) 396 (84.3) 194 (72.7) 182 (68.2)
*Participants with family history information available were only included in the analysis.
NAFLD, Non-alcoholic fatty liver disease; SD, standard deviation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; GGT, gamma-glutamyl transferase.
Among the anthropometric factors, weight and waist
circumference showed incremental change during pre-NAFLD
stage before NAFLD was newly diagnosed (first period for group
2 and second period for group 1) but only in women. SBP and
DBP decreased more in group 1 during the second period and
in group 2 during the first period in women, although without
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FIGURE 2 | Chronological changes of anthropometric and laboratory parameters according to NAFLD development group and gender. (A) Chronological changes of
incremental and decremental changes are presented. (B) Delta difference values of each parameter during two periods are presented (Group 1: patients who newly
developed NAFLD in year 2013; Group 2: patients who newly developed NAFLD in year 2011).
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statistical significance. In men, parameters showed variable
changes in the pre-NAFLD stage periods for the NAFLD group
compared to the control group.
Chronological Changes in Lifestyle Factors
in the NAFLD Subgroups
Among the three lifestyle factors considered in this study, we
observed different patterns by gender (Table 2). In men, we
found no consistent chronological change in pre-NAFLD stage
periods for both groups. In contrast, the proportion of females
with no exercise increased in group 2 during the first period
(+1.46 %) and in group 1 during the second period (+0.77%).
In other words, more NAFLD was diagnosed in female subjects
who did not perform any exercise. Furthermore, the alcohol
consumption scores in females decreased in greater degree in
group 1 during the second period (−0.11) compared to other
groups in the corresponding periods, while men did not show
similar consistent trends.
DISCUSSION
In this study, we evaluated the effects of 18 anthropometric,
laboratory, and lifestyle factors on the development of NAFLD
by comparing chronological changes in parameters in association
with new NAFLD diagnoses. Given a retrospective cohort study
population, we could derive chronological changes for each
subject across a 4-year period using the consistent approach
of national health check-ups. While previous studies in various
populations focused on finding risk factors associated with
NAFLD in a cross-sectional study setting (14), we could reveal
several interesting findings for associations between NAFLD and
changes in measured factors over time, focusing on dynamics in
pre-NAFLD stages according to gender.
Firstly, it is interesting that the serum TG level, which is
normally highlighted for its important role in hyperlipidemia
and metabolic syndrome when increased, is inversely associated
with NAFLD, especially in men. Importantly, the decremental
changes of serum TG level in pre-NAFLD stage were previously
suggested as a potential biomarker to identify critical transition
state for NAFLD in animal model (9). In human studies, a
decrease in serum TG level is generally reported to be associated
with liver cirrhosis (15). It is plausible that the dynamics of
lipid species in serum and liver might be different according to
disease progression, especially in pre-NAFLD stage. Although
serum lipid profiles were previously studied for their associations
with NAFLD (16, 17), chronological changes in liver and serum
according to different NAFLD stages should be investigated
using traditional parameters as well as up-to-date metabolomics
approach (18).
Secondly, the relationship of weight and waist circumference
with development of NAFLD appeared to be stronger in women
than men. Interestingly, one Japanese population study also
showed the similar results that the same degree of weight
gain increased the relative risk for NAFLD more prominently
in women than in men (19). Several researchers have also
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markers is considerably stronger in women than men (20, 21),
which eventually provoke increased inflammation of hepatocytes
leading toNAFLD. Based on previous studies highlighting gender
differences of NAFLD (22), further studies with inflammatory
marker measurements would prove the hypothesis that women
might be more susceptible than men to the inflammatory effects
of central obesity and even development of NAFLD.
Lastly, the effects of exercise on the development of NAFLD
revealed to be stronger in women than men, which is in line with
the previous finding. Many researchers and the NICE guideline
emphasize the importance of exercise for NAFLD management
and control (8, 23). Our results revealed the greatest increases
in sedentary lifestyle among females in the NAFLD patients
during the time period of a new diagnosis of NAFLD, the pre-
NAFLD stage. Although central obesity could be a main reason
for NAFLD development, the degree of physical activity as a
lifestyle risk factor for the development of NAFLD should also
be emphasized (5, 6).
The fundamental limitation of our study is selection bias
associated with any population-based retrospective cohort.
Therefore, we were unable to discern direct causal relationships
between the various factors and NAFLD. However, this is a large
propensity score-matched population study, which promotes
the statistical reliability of the results. Additionally, correlation
analyses and comparative association quantification among
parameters would validate the association of dynamic changes
with NAFLD development, which was not performed in this
study. Another limitation is associated with diagnosis, because
we did not include the current standard diagnostic procedure
of a liver biopsy which might provide NAFLD severity level
for fibrosis. Even though we used several types of diagnostic
parameters, such as HIS and FLI, to increase the confirmatory
degree of NAFLD diagnosis, subjective diagnoses dependent on
different physicians’ medical decisions could still have affected
the analysis, as could code input errors in the database.
In conclusion, we investigated chronological changes in
anthropometric factors, laboratory results, and lifestyle factors to
predict the development of NAFLD during pre-NAFLD stage.
Based on our finding of inversely decreasing pattern in serum
triglycerides during the pre-NAFLD stage, we suggest early
screening strategies for people with abrupt chronological changes
in serum triglycerides to predict NAFLD development before the
progression. Furthermore, people with abrupt and prominent
chronological changes in specific parameters, especially waist
circumference and exercise degree for women, might require
more detailed follow-up evaluations. A better understanding of
the various factors related to NAFLD development will provide
insight into preventive interventions to improve health and
reduce the incidence of NAFLD-associated disorders.
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